研究报告 |
|
|
|
|
真核细胞表达单纯疱疹病毒I型包膜糖蛋白B及其抗原性与免疫原性分析 |
王正茂1,李琳2,管文燕2,李越希1,2** |
1.南京军区军事医学研究所 南京 210002
2.南京医科大学基础医学院生物化学与分子生物学系 南京 210029 |
|
Expression of Herpes Simplex Virus Type I Glycoprotein B in Eukaryotic Cells and Analysis of Its Antigenicity and Immunogenicity |
WANG Zheng-mao1,LI Lin2,GUAN Wen-yan2,LI Yue-xi1,2 |
1.East-China Institute for Medical Biotechniques, Nanjing 210002,China
2.Department of Biochemistry & Molecular Biology,School of Preclinical Medicine, Nanjing Medical University, Nanjing 210029, China |
[1] Eizuru Y. Development of new antivirals for herpesviruses. Antivir Chem Chemother, 2003, 14(6):299308.
[2] Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2seropositive persons: a metaanalysis. J Infect Dis, 2002, 185(1):4552.
[3] Perez G, Skurnick J H, Denny T N, et al. Herpes simplex type II and Mycoplasma genitalium as risk factors for heterosexual HIV transmission: report from the heterosexual HIV transmission study. Int J Infect Dis, 1998, 3(1):511.
[4] Chen C Y, Ballard R C, BeckSague C M, et al. Human immunodeficiency virus infection and genital ulcer disease in South Africa: the herpetic connection. Sex Transm Dis, 2000, 27(1):2129.
[5] Langenberg A G M, Burke R L, Adair S F, et al. A recombinant glycoprotein vaccine for herpes simplex type2: safety and efficacy. Ann Intern Med, 1995, 122(12):889898.
[6] 杨慧兰,周翠,关蕾,等.单纯疱疹病毒II型CTL表位DNA疫苗的Th1/Th2免疫应答研究中国皮肤性病学杂志,2007,21(7):402404 Yang H L, Zhou C, Guan L, et al. Chin J Derm Venereol, 2007, 21(7):402404.
[7] 吕敏,潘明洁,李越希,等.单纯疱疹病毒1型糖蛋白B胞外区基因片段的克隆、表达及初步鉴定.药物生物技术,2008,15(2):9093. Lv M, Pan M J, Li Y X, et al. Pharmaceutical Biotechnology, 2008, 15(2):9093.
[8] Ashley R L, Wald A. Genital herpes: review of the epidemic and potential use of typespecific serology. Clin Microbiol Rev, 1999, 12(1):18.
[9] Stanberry L, Cunningham A, Mertz G, et al. New developments in the epidemiology, natural history, and management of genital herpes. Antiviral Res, 1999, 42(1):114.
[10] Fleming D T, McQuillan G M, Johnson R E, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med, 1997, 337(16):11051111.
[11] Ribes J A, Steele A D, Seabolt J P, et al. Sixyear study of the incidence of herpes in genital and nongenital cultures in a central Kentucky medical center patient population. J Clin Microbiol, 2001, 39(9):33213325.
[12] Tayal S C, Pattman R S. High prevalence of herpes simplex virus type 1 in female anogenital herpes simplex in NewcastleuponTyne 198392. Int J STD AIDS, 1994, 5(5):359361.
[13] Thompson C. Genital herpes simplex typing in genitourinary medicine: 1995–1999. Int J STD AIDS, 2000, 11(8):501502.
[14] Dingwell K S, Brunetti C R, Hendricks R L, et al. Herpes simplex virus glycoproteins E and I facilitate celltocell spread in vivo and across junctions of cultured cells. J Virol, 1994, 68(2):834845.
[15] Spear P G. Membrane fusion induced by herpes simplex virus. In: Bentz J, editor. Viral Fusion Mechanisms. CRC Press, Boca Raton, 1993. 201232.
[16] Berman P W, Dowbenko D, Lasky L(A) Detection of antibodies to herpes simplex virus with a continuous cell line expressing cloned glycoprotein(D) Science, 1983, 222(4623):524527.
[17] Glorioso J, Schroder C H, Kumel G, et al. Immunogenicity of herpes simplex virus glycoproteins gC and gB and their role in protective immunity. J Virol, 1984, 50(3):805812.
[18] Little S P, Jofre J T, Courtney R J, et al. A virion associated glycoprotein essential for infectivity of herpes simplex virus type 1. Virology, 1981, 115(1):149160.
[19] Watson R J, Weis J H, Salstrom J S, et al. Herpes simplex virus type 1 glycoprotein D gene: nucleotide sequence and expression in Escherichia coli. Science, 1982, 218(4570):381384.
[20] Pellett P E, Kousoulas K G, Pereira L, et al. Anatomy of the herpes simplex virus 1 strain F glycoprotein B gene: primary sequence and predicted protein structure of the wild type and of monoclonal antibodyresistant mutants. J Virol, 1985, 53(1):243253.
[21] Nass P H, Elkins K L, Weir J P. Protective immunity against herpes simplex virus generated by DNA vaccination compared to natural infection. Vaccine, 2001, 19 (1112):15381546.
[22] Chen Y, Hu D, Eling D J, et al. DNA vaccines encoding fulllength or truncated Neu induce protective immunity against Neuexpressing mammary tumors. Cancer Res, 1998, 58(9):19651971.
[23] Lin X H, Ali M A, Openshaw H, et al. Deletion of the carboxyterminus of herpes simplex virus type 1 (HSV1) glycoprotein B does not affect oligomerization, heparinbinding activity, or its ability to protect against HSV challenge. Arch Virol, 1996, 141(6):11531165. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|